TRACON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 USD | +0.67% |
|
-7.41% | -57.17% |
| May. 14 | Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9.594 | 179 | 53.87 | 33.1 | 5.453 | 3.413 | - | - |
| Enterprise Value (EV) 1 | 9.594 | 179 | 53.87 | 33.1 | 5.453 | 3.413 | 3.413 | 3.413 |
| P/E ratio | -0.31 x | -6.26 x | -1.67 x | -1.07 x | -1.59 x | -0.46 x | -0.41 x | 25 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 156 x | - | 0.45 x | - | - | 0.12 x |
| EV / Revenue | - | - | 156 x | - | 0.45 x | - | - | 0.12 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | -10,672,538 x | -2,441,646 x | - | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - | - |
| Price to Book | - | - | 4.6 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 205 | 765 | 972 | 1,111 | 1,557 | 2,275 | - | - |
| Reference price 2 | 46.80 | 234.0 | 55.40 | 29.80 | 3.502 | 1.500 | 1.500 | 1.500 |
| Announcement Date | 2/27/20 | 2/25/21 | 3/15/22 | 3/8/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.346 | - | 12.04 | - | - | 29.64 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.3 | -16.22 | -28.35 | -27.89 | -9.273 | -20.22 | -21.5 | -5.478 |
| Operating Margin | - | - | -8,192.77% | - | -76.99% | - | - | -18.48% |
| Earnings before Tax (EBT) 1 | -22.67 | -16.78 | -28.67 | -29.14 | -3.588 | -20.18 | -22.83 | -14.4 |
| Net income 1 | -22.67 | -16.78 | -28.67 | -29.14 | -3.588 | -20.18 | -21.5 | -5.478 |
| Net margin | - | - | -8,285.26% | - | -29.79% | - | - | -18.48% |
| EPS 2 | -149.4 | -37.40 | -33.20 | -27.80 | -2.200 | -3.280 | -3.695 | 0.0600 |
| Free Cash Flow | - | -16.77 | -22.06 | - | - | - | - | - |
| FCF margin | - | - | -6,376.01% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/15/22 | 3/8/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 9 | - | 3.045 | 0.1 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.663 | -9.446 | -6.239 | -6.377 | -5.832 | -7.313 | -0.779 | -1.588 | 0.407 | -3.212 | -4.854 | -5.258 | -5.46 |
| Operating Margin | - | - | - | - | - | - | -8.66% | - | 13.37% | -3,212% | - | - | - |
| Earnings before Tax (EBT) 1 | -7.712 | -9.473 | -6.23 | -6.435 | -6.997 | -8.504 | -6.286 | 10.76 | 0.439 | - | -4.854 | -5.258 | -5.46 |
| Net income 1 | -7.712 | -9.473 | -6.23 | -6.435 | -6.997 | -8.504 | -6.286 | 10.76 | 0.439 | -3.168 | -4.854 | -5.258 | -5.46 |
| Net margin | - | - | - | - | - | - | -69.84% | - | 14.42% | -3,168% | - | - | - |
| EPS 2 | -8.000 | -9.600 | -6.200 | -6.000 | -6.200 | -7.200 | -4.000 | 5.800 | 0.2000 | -1.330 | -2.030 | -0.5300 | -0.5500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 5/11/22 | 8/10/22 | 11/14/22 | 3/8/23 | 5/10/23 | 8/14/23 | 11/9/23 | 3/5/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -16.8 | -22.1 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | 12.00 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 0.05 | - | - | - | - | - |
| Capex / Sales | - | - | 13.87% | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 3/15/22 | 3/8/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.5
USD
Average target price
30.5
USD
Spread / Average Target
+1,933.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.17% | 3.41M | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| -12.97% | 32.79B | |
| +63.50% | 26.23B | |
| -20.71% | 14.52B | |
| -7.31% | 13.09B | |
| -12.64% | 11.5B | |
| -42.60% | 11.6B | |
| +5.17% | 8.82B |
- Stock Market
- Equities
- TCON Stock
- Financials TRACON Pharmaceuticals, Inc.
